Papers Research pointers

Platelet responsiveness to aspirin in patients with hyperlipidaemia

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7380.82 (Published 11 January 2003) Cite this as: BMJ 2003;326:82
  1. Maribeth Friend, graduate studenta,
  2. Ivana Vucenik, associate professora,
  3. Michael Miller, associate professor of medicine and epidemiologyb (mmiller{at}heart.umaryland.edu)
  1. a Department of Medical and Research Technology and Medicine, University of Maryland Medical Center, Baltimore, MD 21201, USA
  2. b Division of Cardiology, University of Maryland Medical Center
  1. Correspondence to: M Miller
  • Accepted 24 June 2002

Platelet responsiveness to aspirin is reduced in patients with hyperlipidaemia

Aspirin 325 mg/day reduces the rate of events associated with coronary heart disease. In most people, aspirin produces irreversible inhibition of platelet aggregation, but in a sizeable minority of patients, the degree of platelet aggregation needed to prevent events according to in vitro assessments is not achieved.1 Risk factors for coronary heart disease may contribute to aspirin resistance (the inability of aspirin to protect individuals from thrombotic complications), so aspirin may not be cardioprotective in patients with hyperlipidaemia.2 We evaluated patients with a range of cholesterol concentrations to determine the impact of hypercholesterolaemia on platelet responsiveness in patients treated with aspirin.

Participants, methods, and results

Consecutive patients (n=56) were recruited from the University of Maryland Preventive Cardiology Outpatient Center. The mean (SD) age was 54.3 (11.1) years, and 40 (72%) of the patients were men. Patients were eligible if they were taking aspirin 325 mg/day and presented with a history of coronary heart disease or at least two risk factors for coronary heart disease. Patients were excluded if they used heparin, warfarin, or other antiplatelet agents or had consumed ethanol within 96 hours of enrolment. The study was approved by the university's institutional review board.

Whole blood was drawn into tubes containing 3.2% buffered sodium citrate and was tested within four hours. Platelet aggregation was assessed by electrical impedance with a dual sample aggregometer and a final concentration of collagen of 1.0 μg/ml. 3 4 Fasting concentrations of total cholesterol and triglycerides in plasma were measured with commercial kits and an automatic chemistry analyser. Concentrations of high density lipoprotein (HDL) cholesterol were measured after apolipoprotein B-containing lipoproteins were precipitated out. The concentration of low density lipoprotein (LDL) cholesterol was calculated by subtracting the sum of the concentration of HDL cholesterol and one fifth of the concentration of triglycerides from the total cholesterol concentration. Hyperlipidaemia was defined as a total cholesterol concentration >6.2 mmol/l. Poor platelet responsiveness to aspirin was defined as aggregation of ≥50% of platelets and represented the top quarter of samples.

The 14 patients with poor responsiveness to aspirin had significantly higher mean (SD) concentrations of total cholesterol and LDL cholesterol, respectively, than the 42 patients with good responsiveness (6.2 (1.6) vs 4.8 (1.2), P=0.004, and 4.0 (1.7) vs 3.0 (1.1), P=0.03). In total, 9/13 (69%) patients with hyperlipidaemia had poor responsiveness to aspirin. No significant differences in concentrations of HDL cholesterol and triglycerides, history of cigarette smoking, or prevalence of hypertension or diabetes mellitus were seen between those with poor and good responsiveness to aspirin. Interestingly, 12/14 (86%) patients with poor responsiveness to aspirin were taking lipid lowering therapy.

Significant correlations were seen between the degree of platelet aggregation produced by 1 μg/ml of collagen and the concentrations of total cholesterol (r=0.35, P=0.009) (figure) and of triglycerides (P=0.049). Correlations were not seen with concentrations of HDL cholesterol or LDL cholesterol; the lack of correlation with LDL cholesterol may have been, in part, because LDL cholesterol concentrations could not be estimated for four patients with hypertriglyceridaemia (triglycerides >4.5 mmol/l).

Figure1

Scattergram of platelet aggregation and total cholesterol concentration

We compared platelet aggregation in patients in the top and bottom quarters of total cholesterol concentrations. Patients with total cholesterol concentrations <4.14 mmol/l (bottom quarter) produced less platelet aggregation, and thus had better platelet responsiveness to aspirin, than patients in the upper quarter of cholesterol concentrations (7% v 64%; P=0.004 by χ2 analysis).

Comment

Despite the cardiovascular benefits of cholesterol lowering treatments, morbidity and mortality from coronary heart disease are unacceptably high. Platelets taken from hyperlipidaemic patients are highly thrombogenic, but other factors, such as upregulation of cyclooxygenase-2 expression, may contribute to poor platelet responsiveness to aspirin. 2 5 Patients who respond poorly to aspirin may need higher doses of aspirin, alternative antiplatelet agents (such as clopidogrel), or further reductions in concentrations of total cholesterol and LDL cholesterol.

Acknowledgments

Contributors: MF, IV, and MM designed the study and wrote the paper. MF and MM did the analysis. IV and MM edited the paper. IV and MM are guarantors for the paper.

Footnotes

  • Funding Supported in part by NIH grant (HL 61369) and a Veteran's Affairs Merit Award to MM.

  • Competing interests None declared.

References

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
View Abstract